Advertisement
NCNA vs TAOX
Which Stock Would AI Choose? NuCana plc (NCNA) vs. TAO Synergies Inc. (TAOX) Stock Comparison
Key Takeaways
- NCNA (NuCana plc) is a clinical-stage oncology biopharmaceutical company with no approved products, while TAOX (TAO Synergies Inc.) is a digital-asset treasury company centered on the Bittensor "TAO" token.
- The two companies operate in fundamentally different markets: NCNA competes in cancer drug development, whereas TAOX is tied to cryptocurrency and artificial intelligence (AI) exposure.
- Relative performance has diverged sharply, with TAOX showing strong trailing gains tied to crypto momentum and NCNA trading near multi-year lows after heavy dilution.
- Both are micro-cap, high-beta, speculative names with elevated volatility and thin institutional ownership.
- Risk profiles differ: NCNA faces clinical and financing risk, while TAOX faces digital-asset price volatility and concentration risk.
Introduction
Investors evaluating small-cap opportunities often weigh very different risk-reward profiles side by side. This stock comparison examines NCNA, a clinical-stage biopharmaceutical company, and TAOX, a digital-asset treasury company. Although both trade on Nasdaq and share a sub-$100 million market-cap profile, their drivers could hardly be more distinct. NuCana is a wager on cancer drug development, while TAO Synergies is effectively a public vehicle for Bittensor's TAO cryptocurrency. This comparison may interest traders evaluating relative momentum and market positioning, as well as investors assessing how sector exposure, catalysts, and financing strategies shape micro-cap risk.
NCNA Overview and Recent Performance
NCNA, or NuCana plc, is a clinical-stage biopharmaceutical company headquartered in Edinburgh, United Kingdom. The company applies its ProTide technology to transform conventional chemotherapy agents, called nucleoside analogs, into medicines intended to generate higher concentrations of anti-cancer metabolites in tumor cells. Its pipeline includes NUC-7738, being studied in advanced solid tumors and melanoma, and NUC-3373, being evaluated in advanced solid tumors and lung cancer.
Recent market activity has been challenging for the stock. NuCana has undergone significant share restructuring, including a 1-for-200 reverse split, and the company has raised capital through equity offerings and an at-the-market (ATM) facility, which has diluted existing shareholders. In recent weeks and months, the share price has trended lower and trades near the low end of its 52-week range. Positively, the company has reported clinical data for NUC-7738 in PD-1-resistant melanoma and secured a composition-of-matter patent for NUC-7738 in China. However, with no approved products or revenue, sentiment remains heavily tied to clinical milestones and the company's ability to fund ongoing trials.
TAOX Overview and Recent Performance
TAOX, or TAO Synergies Inc., is a New York-based company that has pivoted from its former identity as Synaptogenix, a biopharmaceutical developer, into a digital-asset treasury company. Its core strategy is the acquisition and staking of TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network focused on machine learning and AI. The company retains legacy biopharmaceutical assets, but its operational focus and value are now tied primarily to the price of the TAO token.
In recent months, TAO Synergies has recorded its first staking revenue and has expanded its digital-asset holdings while trimming cash reserves. The company was also added to a Russell microcap index, a milestone that can affect index-tracking demand. The stock has experienced substantial trailing gains over the past year, driven largely by cryptocurrency and AI sentiment, though it has also shown sharp pullbacks consistent with the volatility of digital assets. Its market positioning remains closely linked to the underlying TAO token's price action rather than traditional corporate fundamentals.
Trending AI Robots
For traders seeking a more systematic approach to evaluating names like these, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading tools. Tickeron hosts hundreds of AI Trading Bots that monitor thousands of different tickers, but only the bots best suited to current market conditions are featured in this section. Each bot carries its own trading style, strategy, timeframe, performance statistics, and universe of tickers, giving users a way to compare automated approaches side by side. For investors interested in adding a data-driven layer to their stock comparison process, exploring the Trending AI Robots section can be a useful next step.
Head-to-Head Comparison
The contrast between these two stocks is stark. NCNA is a pure-play biotech whose value depends on clinical trial outcomes, regulatory milestones, and continued access to capital. TAOX, by contrast, functions as a proxy for a single cryptocurrency, making its market positioning a function of digital-asset sentiment and token prices rather than earnings or cash flow.
Growth drivers also diverge. NCNA's upside rests on data readouts and potential partnership or licensing deals, events that are binary and often delayed. TAOX's trajectory depends on TAO token appreciation and staking yield, which can compound quickly but also reverse abruptly. On risk factors, NCNA faces ongoing dilution and the inherent failure rate of early-stage drug programs, while TAOX faces concentration in a single volatile digital asset, evolving regulation, and a highly illiquid micro-cap structure.
From a momentum standpoint, TAOX has shown stronger trailing relative performance, while NCNA has lagged amid restructuring. Neither stock offers institutional-grade stability, and both carry betas well above the broader market, indicating amplified swings relative to major indices.
Tickeron AI Verdict
Based on observable trend consistency, relative positioning, and recent catalysts, Tickeron's AI would likely tilt toward TAOX in the current environment. The company has demonstrated a clearer near-term momentum profile, a defined catalyst in the form of the TAO token's price action, and improving market positioning following its index inclusion. NCNA, by contrast, remains in a consolidation phase marked by dilution and uncertain clinical timelines. This assessment is probabilistic rather than definitive: digital-asset volatility and biotech clinical risk could shift the relative picture quickly, and neither name is suitable for risk-averse investors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NCNA is a StrongBuy and TAOX is a Hold.
NCNA's RSI Oscillator remains in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where NCNA advanced for three days, in 164 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
NCNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NCNA as a result. In 87 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NCNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NCNA entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.198) is normal, around the industry mean (2.988). P/E Ratio (0.019) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. NCNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for TAOX turns negative, indicating new downward trend
TAOX saw its Momentum Indicator move below the 0 level on October 07, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 88 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TAOX turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 46 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TAOX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TAOX crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAOX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TAOX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TAOX's RSI Oscillator exited the oversold zone, 27 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TAOX advanced for three days, in 189 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
TAOX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. TAOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.081) is normal, around the industry mean (3.638). P/E Ratio (2.148) is within average values for comparable stocks, (8.944). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.809). Dividend Yield (0.000) settles around the average of (7.191) among similar stocks. P/S Ratio (30.303) is also within normal values, averaging (16.763).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TAOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
NCNA | TAOX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 52 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 88 | 82 | |
P/E GROWTH RATING 1..100 | 4 | 41 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NCNA's Valuation (50) in the Biotechnology industry is somewhat better than the same rating for TAOX (95) in the null industry. This means that NCNA’s stock grew somewhat faster than TAOX’s over the last 12 months.
NCNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as TAOX (100) in the null industry. This means that NCNA’s stock grew similarly to TAOX’s over the last 12 months.
NCNA's SMR Rating (98) in the Biotechnology industry is in the same range as TAOX (99) in the null industry. This means that NCNA’s stock grew similarly to TAOX’s over the last 12 months.
TAOX's Price Growth Rating (82) in the null industry is in the same range as NCNA (88) in the Biotechnology industry. This means that TAOX’s stock grew similarly to NCNA’s over the last 12 months.
NCNA's P/E Growth Rating (4) in the Biotechnology industry is somewhat better than the same rating for TAOX (41) in the null industry. This means that NCNA’s stock grew somewhat faster than TAOX’s over the last 12 months.
| NCNA | TAOX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | N/A | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 16 days ago 78% | 2 days ago 81% |
| Declines ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NCNA’s FA Score shows that 1 FA rating(s) are green while TAOX’s FA Score has 0 green FA rating(s).
- NCNA’s FA Score: 1 green, 4 red.
- TAOX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NCNA’s TA Score shows that 4 TA indicator(s) are bullish while TAOX’s TA Score has 4 bullish TA indicator(s).
- NCNA’s TA Score: 4 bullish, 3 bearish.
- TAOX’s TA Score: 4 bullish, 6 bearish.
Price Growth
NCNA (@Biotechnology) experienced а -8.37% price change this week, while TAOX (@Investment Banks/Brokers) price change was +1.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
The average weekly price growth across all stocks in the @Investment Banks/Brokers industry was -5.17%. For the same industry, the average monthly price growth was -16.77%, and the average quarterly price growth was -12.77%.
Reported Earning Dates
NCNA is expected to report earnings on Nov 12, 2026.
TAOX is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Investment Banks/Brokers (-5.17% weekly)These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.
Advertisement
NCNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NCNA has been closely correlated with TAOX. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To NCNA | 1D Price Change % | ||
|---|---|---|---|---|
| NCNA | 100% | -2.94% | ||
| TAOX - NCNA | 92% Closely correlated | +4.88% | ||
| PALI - NCNA | 81% Closely correlated | -2.10% | ||
| PLX - NCNA | 34% Loosely correlated | -2.65% | ||
| IOVA - NCNA | 34% Loosely correlated | -1.62% | ||
| DMRA - NCNA | 31% Poorly correlated | +4.16% | ||
More | ||||
TAOX and
Correlation & Price change
A.I.dvisor indicates that over the last year, TAOX has been closely correlated with NCNA. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if TAOX jumps, then NCNA could also see price increases.
| Ticker / NAME | Correlation To TAOX | 1D Price Change % | ||
|---|---|---|---|---|
| TAOX | 100% | +4.88% | ||
| NCNA - TAOX | 92% Closely correlated | -2.94% | ||
| RNAC - TAOX | 91% Closely correlated | +0.39% | ||
| AGEN - TAOX | 91% Closely correlated | -0.31% | ||
| ALLR - TAOX | 87% Closely correlated | -0.62% | ||
| NRXP - TAOX | 84% Closely correlated | +0.38% | ||
More | ||||